BioAlliance Pharma Strengthens Sitavig Patent Protection with New U.S. and South Korean issued Patents

U.S. exclusivity prolonged until 2029

Paris, November 14, 2013 - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative company dedicated to the development of orphan oncology and to supportive care products, announces the issuance of two new patents for Sitavig® (acyclovir mucoadhesive tablet) by the U.S. and South Korean patent offices. Sitavig® is approved in the U.S. and eight European countries (Sweden, the U.K., Spain, Italy, Denmark, Finland, Norway and Poland) for the treatment of recurrent labial herpes in adults.

Sitavig's patent protection is now further enhanced with:

- The issuance of a third patent family in the U.S. based on the administration scheme, a single application of Sitavig® that covers the entire herpes outbreak episode. This new patent extends Sitavig market exclusivity for two additional years, until December 2029 in Sitavig's first commercial market.

- The extension of the second patent family with a new issuance from the South Korean Patent Office. After Europe, the United States, China and Japan, the South Korean office has granted the patent based on Sitavig's original manufacturing process, which gives the product its special adhering property.

This set of three patent families and patent applications therefore reinforces Sitavig's market protection and gives Sitavig strong exclusivity until 2029 in key international markets.

"These grants mirror our industrial protection strategy which is to maximize the value of the products in our pipeline with the best possible exclusivity. Sitavig®'s extended protection until 2029 in the U.S. should help facilitate discussions with potential business partners," said Aude Michel, Director of Business Development BioAlliance Pharma.

About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharmaôs ambition is to become a leading player in these fields by coupling innovation to patient needs. The companyôs teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 26 countries (EU, US, Korea), commercialized in Europe and in the US.
Sitavig® (Acyclovir Lauriad®) (labialis herpes): Registered in the US and in 8 European countries, registration status in the other European countries.
Fentanyl Lauriad® (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products
Livatag® (Doxorubicin TransdrugÊ) (primary liver cancer): Phase III on going
Validive® (Clonidine Lauriad®) (mucositis): Phase II on going
AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2012 Reference Document filed with the AMF on April 18, 2013, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Judith Greciet, CEO
judith.greciet@bioalliancepharma.com
Nicolas Fellmann, CFO
nicolas.fellmann@bioalliancepharma.com
Tel.: +33 1 45 58 76 00

ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
caroline@alizerp.com
Christian Berg
+33 6 31 13 76 20
christian@alizerp.com